Spots Global Cancer Trial Database for advanced solid tumours
Every month we try and update this database with for advanced solid tumours cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Phase I Study of AT13148, a Novel AGC Kinase Inhibitor | NCT01585701 | Advanced Solid ... | AT13148 | 18 Years - | Cancer Research UK | |
| BT1718 in Patients With Advanced Solid Tumours. | NCT03486730 | Advanced Solid ... Non-Small Cell ... Non-Small Cell ... Oesophageal Can... | BT1718 | 16 Years - | Cancer Research UK | |
| Capivasertib China PK Study | NCT04742036 | Advanced Solid ... | Capivasertib Paclitaxel | 18 Years - 130 Years | AstraZeneca | |
| Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours | NCT02042781 | Advanced Solid ... | PG545 | 18 Years - | Zucero Pty Ltd | |
| Study to Investigate the Management of Hypertension and Efficacy of AZD2171 in Patients With Advanced Solid Tumours | NCT00264004 | Tumors | AZD2171 | 18 Years - | AstraZeneca | |
| Capivasertib China PK Study | NCT04742036 | Advanced Solid ... | Capivasertib Paclitaxel | 18 Years - 130 Years | AstraZeneca | |
| A Study Investigating DNA-damage Response Agents in Molecularly Altered Advanced Cancer | NCT04564027 | Advanced Solid ... | Ceralasertib | 18 Years - 130 Years | AstraZeneca | |
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours | NCT05154604 | Advanced Solid ... | SHR-A1921 | 18 Years - | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | |
| Trial of Olaparib in Combination With AZD5363 (ComPAKT) | NCT02338622 | Advanced Cancer | olaparib AZD5363 | 18 Years - | Royal Marsden NHS Foundation Trust | |
| A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours | NCT05154604 | Advanced Solid ... | SHR-A1921 | 18 Years - | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | |
| The Pharmacokinetics and Safety of Olaparib Alone and With Paclitaxel in Chinese Patients With Advanced Solid Tumour. | NCT02430311 | Advanced Solid ... | Olaparib Paclitaxel Olaparib | 18 Years - 130 Years | AstraZeneca | |
| Phase I Study of AT13148, a Novel AGC Kinase Inhibitor | NCT01585701 | Advanced Solid ... | AT13148 | 18 Years - | Cancer Research UK | |
| A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours | NCT04949425 | Advanced Solid ... | Adavosertib | 18 Years - 130 Years | AstraZeneca | |
| Phase 1 Trial of CXD101 in Patients With Advanced Cancer | NCT01977638 | Advanced Cancer | CXD101 | 18 Years - | Oxford University Hospitals NHS Trust | |
| Phase I Study of AT13148, a Novel AGC Kinase Inhibitor | NCT01585701 | Advanced Solid ... | AT13148 | 18 Years - | Cancer Research UK | |
| Study to Assess the Safety and Preliminary Efficacy of AZD0156 at Increasing Doses Alone or in Combination With Other Anti-cancer Treatment in Patients With Advanced Cancer | NCT02588105 | Advanced Solid ... | AZD0156 Olaparib irinotecan Fluorouracil Folinic Acid | 18 Years - 130 Years | AstraZeneca | |
| A Study to Assess RXC004 Efficacy in Advanced Solid Tumours After Progression on Standard of Care (SoC) Therapy (PORCUPINE2) | NCT04907851 | Advanced Solid ... | RXC004 RXC004 RXC004 Denosumab pembrolizumab | 18 Years - | Redx Pharma Plc | |
| Phase Ib Study AZD1775 in Combination With Carboplatin and Paclitaxel in Adult Asian Patients With Solid Tumours | NCT02341456 | Advanced Solid ... | AZD1775 Paclitaxel carboplatin | 18 Years - 100 Years | AstraZeneca | |
| A Study to Assess the Effects of Itraconazole, Rifampicin, and Omeprazole on Pharmacokinetics of Adavosertib | NCT04959266 | Advanced Solid ... | Adavosertib Itraconazole Rifampicin Omeprazole | 18 Years - 130 Years | AstraZeneca | |
| A Phase 1/2 Study of [225Ac]-FPI-1434 Injection | NCT03746431 | Advanced Solid ... Endometrial Can... Cervical Cancer Ovarian Cancer Breast Cancer Triple Negative... HER2-negative B... Head and Neck S... Adrenocortical ... Uveal Melanoma | [111In]-FPI-154... [225Ac]-FPI-143... FPI-1175 Infusi... [225Ac]-FPI-143... | 18 Years - | Fusion Pharmaceuticals Inc. | |
| EMD 640 744 in Montanide ISA 51 VG Administered in Subjects With Advanced Solid Tumors | NCT01012102 | Advanced Solid ... | EMD 640744 EMD 640744 EMD 640744 Montanide ISA 5... Montanide ISA 5... Montanide ISA 5... | 18 Years - | Merck KGaA, Darmstadt, Germany | |
| First Time in Human Study of AZD8701 With or Without Durvalumab in Participants With Advanced Solid Tumours | NCT04504669 | Clear Cell Rena... Non-Small-Cell ... Triple Negative... Squamous Cell C... Small Cell Lung... Gastroesophagea... Melanoma Cervical Cancer Advanced Solid ... | AZD8701 Durvalumab | 18 Years - 101 Years | AstraZeneca | |
| A Study to Assess the Safety and Tolerability of RC88 for Patients With Advanced Solid Tumours | NCT05508334 | Advanced Solid ... | RC88 | 18 Years - 70 Years | RemeGen Co., Ltd. | |
| Trial of Olaparib in Combination With AZD5363 (ComPAKT) | NCT02338622 | Advanced Cancer | olaparib AZD5363 | 18 Years - | Royal Marsden NHS Foundation Trust | |
| A Study of IMP4297 in Patients With Advanced Solid Tumors | NCT03508011 | Advanced Solid ... Breast Cancer Ovarian Cancer Prostate Cancer | IMP4297 | 18 Years - 70 Years | Impact Therapeutics, Inc. | |
| A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours | NCT01058538 | Advanced Solid ... | L19IL2 | 18 Years - | Philogen S.p.A. | |
| Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours | NCT02042781 | Advanced Solid ... | PG545 | 18 Years - | Zucero Pty Ltd | |
| Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours | NCT01859351 | Advanced Solid ... | WX-037 WX-554 | 18 Years - | Heidelberg Pharma AG | |
| A Study of PM1021 (Anti-TIGIT) With or Without PM8001 (Anti-PD-L1/TGF-β) in Patients With Advanced Solid Tumours | NCT05537051 | Advanced Solid ... | PM1021, PM8001 | 18 Years - 75 Years | Biotheus Inc. | |
| Phase I Study of AT13148, a Novel AGC Kinase Inhibitor | NCT01585701 | Advanced Solid ... | AT13148 | 18 Years - | Cancer Research UK | |
| A Study of SHR-A1921 for Injection in Subjects With Advanced Solid Tumours | NCT05154604 | Advanced Solid ... | SHR-A1921 | 18 Years - | Suzhou Suncadia Biopharmaceuticals Co., Ltd. | |
| Phase I Comparative Bioavailability Study | NCT00777582 | Solid Tumors | AZD2281 | 18 Years - 130 Years | AstraZeneca | |
| Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours | NCT03518606 | Advanced Solid ... Breast Cancer Head and Neck C... Cervix Cancer Prostate Cancer | Durvalumab + Tr... | 18 Years - | UNICANCER | |
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| Phase I/II Dose-escalation Study to Investigate Safety and Pharmacokinetics/ Pharmacodynamics of WX-554 in Patients With Solid Tumours | NCT01581060 | Advanced Solid ... | WX-554 | 18 Years - | Heidelberg Pharma AG | |
| A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours | NCT01058538 | Advanced Solid ... | L19IL2 | 18 Years - | Philogen S.p.A. | |
| A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours | NCT04949425 | Advanced Solid ... | Adavosertib | 18 Years - 130 Years | AstraZeneca | |
| Effect of Food Upon Pharmacokinetics of Single Oral Dose of Cediranib (AZD2171, Recentin™) | NCT00306891 | Cancer | Cediranib Cediranib 30 - ... | 18 Years - | AstraZeneca | |
| AZD1152 in Patients With Advanced Solid Malignancies-Study 3 | NCT00497679 | Solid Tumours | AZD1152 | 18 Years - | AstraZeneca | |
| Safety, Tolerability and Pharmacokinetics of AZD1775 (Adavosertib) Plus MEDI4736 (Durvalumab) in Patients With Advanced Solid Tumours | NCT02617277 | Advanced Solid ... | AZD1775 MEDI4736 | 18 Years - 130 Years | AstraZeneca | |
| Metronomic Oral Vinorelbine Plus Anti-PD-L1/Anti-CTLA4 ImmunothErapy in Patients With Advanced Solid Tumours | NCT03518606 | Advanced Solid ... Breast Cancer Head and Neck C... Cervix Cancer Prostate Cancer | Durvalumab + Tr... | 18 Years - | UNICANCER | |
| Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer | NCT00515866 | Pancreatic Neop... | KU-0059436 (AZD... Gemcitabine | 18 Years - | AstraZeneca | |
| Study of Adavosertib(AZD1775) in Japanese Patients With Advanced Solid Tumours | NCT04462952 | Advanced Solid ... | Adavosertib (AZ... | 20 Years - 120 Years | AstraZeneca | |
| Phase 1 Trial of CXD101 in Patients With Advanced Cancer | NCT01977638 | Advanced Cancer | CXD101 | 18 Years - | Oxford University Hospitals NHS Trust | |
| A Study of RC88 Combined With Sintilimab for Advanced Solid Tumours | NCT05804526 | Advanced Solid ... | RC88 Sintilimab Inje... | 18 Years - 70 Years | RemeGen Co., Ltd. | |
| Phase-2 Dacomitinib Study on Patients With EGFR-Driven Advanced Solid Tumours With Low EGFR-AS1 IncRNA Expr or Other Novel Emerging Biomarkers | NCT04946968 | Advanced Solid ... Non-small Cell ... Head and Neck S... | Oral Dacomitini... | 21 Years - 99 Years | National Cancer Centre, Singapore | |
| IMP4297 in Combination With Temozolomide in Patients With Advanced Solid Tumors and Small Cell Lung Cancer | NCT04434482 | Advanced Solid ... Small Cell Lung... | IMP4297(senapar... | 18 Years - | Impact Therapeutics, Inc. | |
| Safety Study of Increasing Doses of Combretastatin in Combination With Bevacizumab (Avastin) in Patients With Advanced Solid Tumors | NCT00395434 | Tumors | Combretastatin ... Bevacizumab (Av... | 18 Years - | Mateon Therapeutics | |
| Phase 1 Trial of CXD101 in Patients With Advanced Cancer | NCT01977638 | Advanced Cancer | CXD101 | 18 Years - | Oxford University Hospitals NHS Trust | |
| A Phase I Study of Safety, Tolerability, and PK of AZD2811 in Patients With Advanced Solid Tumors. | NCT02579226 | Advanced Solid ... | AZD2811 | 18 Years - 130 Years | AstraZeneca | |
| Preliminary Anti-tumour Activity of mTor Kinase Inhibitor in Advanced Tumours | NCT01194193 | Cancer Advanced Solid ... Lymphomas | AZD8055 | 18 Years - | AstraZeneca | |
| First in Human Study of AZD9592 in Solid Tumors | NCT05647122 | Advanced Solid ... Carcinoma Non-s... Head and Neck N... Colorectal Neop... | AZD9592 Osimertinib 5-Fluorouracil ... Leucovorin Bevacizumab | 18 Years - | AstraZeneca | |
| Study of the Effect of Rifampicin on the Pharmacokinetics (PK) of Multiple Doses of Cediranib in Patients With Solid Tumours | NCT00750841 | Solid Tumors | cediranib | 18 Years - 130 Years | AstraZeneca | |
| A Study to Assess the Safety and Tolerability of Adavosertib for Patients With Advanced Solid Tumours | NCT04949425 | Advanced Solid ... | Adavosertib | 18 Years - 130 Years | AstraZeneca | |
| NUC-1031 in Patients With Advanced Solid Tumours | NCT01621854 | Cancer | NUC-1031 | 18 Years - | Imperial College London | |
| Phase I Study of WX-037 Alone and in Combination With WX-554 in Solid Tumours | NCT01859351 | Advanced Solid ... | WX-037 WX-554 | 18 Years - | Heidelberg Pharma AG | |
| AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer | NCT03421353 | Advanced Solid ... | AZD9150 Durvalumab Cisplatin 5-Flourouracil Carboplatin Gemcitabine Nab-paclitaxel | 18 Years - 130 Years | AstraZeneca | |
| A Dose Finding Pharmacokinetic Study of the Tumour-targeting Human L19IL2 Monoclonal Antibody-Cytokine Fusion Protein in Patients With Advanced Solid Tumours | NCT01058538 | Advanced Solid ... | L19IL2 | 18 Years - | Philogen S.p.A. | |
| AZD9150 Plus Durvalumab Alone or in Combination With Chemotherapy in Patients With Advanced, Solid Tumours and in Patients With Non-Small-Cell Lung Cancer | NCT03421353 | Advanced Solid ... | AZD9150 Durvalumab Cisplatin 5-Flourouracil Carboplatin Gemcitabine Nab-paclitaxel | 18 Years - 130 Years | AstraZeneca | |
| Pantoprazole With Doxorubicin for Advanced Cancer Patients With Extension Cohort of Patients With Solid Tumours | NCT01163903 | Advanced Solid ... | pantoprazole so... doxorubicin hyd... | 18 Years - | University Health Network, Toronto | |
| Study to Assess the Safety & Tolerability of a PARP Inhibitor in Combination With Gemcitabine in Pancreatic Cancer | NCT00515866 | Pancreatic Neop... | KU-0059436 (AZD... Gemcitabine | 18 Years - | AstraZeneca |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
